ARS Pharmaceuticals, Inc. (SPRY) Institutional Ownership

Ownership Summary

A total of 180 institutions have reported a stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) as of December 2025, according to recent 13F filings with the SEC.

• The collective stake of institutional investors in ARS Pharmaceuticals moved to 91.1% in December 2025, a shift up from the 85.1% reported for September 2025.
• In percentage terms, this reflects as a holdings change of 15.49% quarter on quarter, and an increase of 9.09% year over year.
• The latest 13F cycle for ARS Pharmaceuticals reveals that of 180 total investors, 89 funds grew their exposure, whereas 51 reduced theirs and 40 made no changes.
• This class of investors increased its holdings in ARS Pharmaceuticals to 89.66Mn shares for the 13F-cycle ending December 2025, up by 12.03Mn shares quarter on quarter, and up 18.34Mn shares year over year.
• With 10.86Mn shares, RA CAPITAL MANAGEMENT, L.P. commands the largest institutional position in ARS Pharmaceuticals as of December 31, 2025, equating to 11.04% of the company.
• Among the most significant buyers of ARS Pharmaceuticals during December 2025 were Tyro Capital Management LLC (3.99Mn), MILLENNIUM MANAGEMENT LLC (3.17Mn), Rubric Capital Management LP (1.70Mn), UBS Group AG (1.55Mn), FIL Ltd (810.07K).
• Leading sellers of ARS Pharmaceuticals stock in December 2025 included ALLIANCEBERNSTEIN L.P. (2.58Mn), Eversept Partners, LP (724.92K), GOLDMAN SACHS GROUP INC (513.70K), Trexquant Investment LP (481.62K), FMR LLC (343.55K).
• The top 10 institutional holders of ARS Pharmaceuticals for the quarter ending December 2025 included RA CAPITAL MANAGEMENT, L.P. (10.86Mn), ORBIMED ADVISORS LLC (8.29Mn), DEERFIELD MANAGEMENT COMPANY, L.P. (7.50Mn), Rubric Capital Management LP (6.20Mn), BlackRock, Inc. (5.09Mn), SR ONE CAPITAL MANAGEMENT, LP (4.01Mn), Tyro Capital Management LLC (3.99Mn), Aberdeen Group plc (3.56Mn), VANGUARD GROUP INC (3.51Mn), STATE STREET CORP (3.22Mn).